New drug hope for aggressive breast cancer

Women with an aggressive type of breast cancer have been offered new hope of a targeted treatment for the condition.

Irish scientists have found a potential new way to treat triple negative breast cancer, which currently has limited treatment options.

They have shown that a new drug, called THZ-1, can prevent triple negative breast cancer. It occurs in one in five women diagnosed with breast cancer and is more likely to affect younger women.

The discovery was made by scientists from Breast-Predict, a collaborative research centre funded by the Irish Cancer Society and an EU-funded research consortium called RATHER.

Triple negative breast cancer is defined as a breast cancer that is negative for oestrogen receptor, negative for progesterone receptor and negative for HER2.

Patients with the resistant form of breast cancer cannot receive targeted therapies such as hormone therapy and can only rely on chemotherapy.

Although many patients do respond well to chemotherapy, a resistance of the tumour to this treatment is a common problem.

Patients with triple negative breast cancer have a poor prognosis, and their tumours are more likely to return and spread following treatment.

The study, published in the journal Cancer Research, looked at a protein called CDK7, found to be present at high levels in triple negative breast cancers. It found that patients with elevated levels of the CDK7 present in their tumour were more likely to experience a disease relapse following standard chemotherapy treatment.

High CDK7 levels could be used as a biomarker to identify patients unlikely to respond well to chemotherapy.

The test could be beneficial to their doctors, as they could then prioritise these patients for a more aggressive treatment regime.

The researchers also tested a drug that acts on CDK7, called THZ-1, to investigate if this could be a novel treatment for triple negative breast cancer. Remarkably, treating triple negative breast cancer cells grown in the laboratory with THZ-1 halted their growth, both on its own and in combination with other treatments.

The researchers proposed THZ-1 as a novel treatment option for this aggressive cancer type, particularly in combination with existing treatments, to improve their success rate.

Professor of cancer biology at UCD, William Gallagher, who led the research, said it opened up an important new treatment possibility for patients with triple negative breast cancer.

Prof Gallagher said: “While further research is needed on this novel treatment before it can be used in breast cancer patients, this work is a key step in opening up a wider range of new and less toxic treatment options for triple negative breast cancer patients.”

Head of research at the Irish Cancer Society, Dr Robert O’Connor, described the research as a significant milestone in the ongoing work of Breast-Predict.


Related Articles

Carlow's Shauntelle Tynan returning home following successful cancer treatment in US

Objection blocks Mercy University Hospital’s cancer care centre in Cork

'I had my honeymoon in Vincent's' - Designer Helen Cody tells of six-hour cancer surgery

BBC DJ Mark Radcliffe has cancer of the tongue – how common is it and what are the signs?


Breaking Stories

Cannabis worth €325,000 seized in Sligo

President Michael D Higgins: 'Let the audit committee look at everything'

Brexit extension not an alternative to legally binding backstop, Taoiseach says

‘Gay cake’ bakery closes Belfast branch

Breaking Stories

This clever new app can help new parents decide if their baby needs to see a doctor

‘Acne won’t stop me living my life’ – Millie Mackintosh on how she got her skin under control

'Jesus, did I paint them?’; Robert Ballagh reacts to the nude portraits to him and his wife

Here's what you can expect from Making a Murderer 2

More From The Irish Examiner